Daiichi Sankyo’s antibody-drug conjugate (ADC) franchise has generated another massive licensing deal, this time from MSD, which is paying $4 billion upfront for rights to three cancer candidates in a deal that could be worth up to $22 billion.The agreement includes another $1.5 billion in spaced payments over the next two years, plus $16.5 billion […]

Author